Pedro Nicolau-Neto

12PUBLICATIONS
54CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumoursMolecular targetsBiomechanical engineering
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Oct 08, 2026
Synergistic Cytotoxicity of Cafestol and Kahweol With Doxorubicin in Breast Cancer Cells Involves TNF‑α Targeting and NF‑κB Downregulation.

|Oct 08, 2025
Patterns of Cervical Metastases and Implications for Neck Management in Minor Salivary Gland Cancer Treatment.

Eduardo Wanderley Estanislau da Costa, Pedro Nicolau-Neto, Paula Moretz-Sohn

|May 14, 2025
ESR1 overexpression is a biomarker of relapse and worse prognosis in stage I endometrioid endometrial carcinoma.

C B P Chaves, P Nicolau-Neto, T A Simão

|Nov 27, 2024
HOXA7 Expression Is an Independent Prognostic Biomarker in Esophageal Squamous Cell Carcinoma.

Jennifer Vieira Gomes, Pedro Nicolau-Neto, Júlia Nascimento de Almeida

|Jan 25, 2024
Microarray data analysis of antileukemic action of Cinnamoylated benzaldehyde LQB-461 in Jurkat cell line.

Rachell R C Thimoteo, Pedro Nicolau Neto, Debora S S Costa

|Jan 10, 2024
ALCAM is a biomarker of tumor aggressiveness and worse prognosis in glottic laryngeal squamous cell carcinoma.

Pedro Nicolau-Neto, Bernardo Cacciari Peryassú, Flávia Nascimento de Carvalho

Pageof 2

Frequent Collaborators

6 joint publications

Tatiana de Almeida Simão

3 joint publications

L F Ribeiro Pinto

3 joint publications

Sheila Coelho Soares-Lima

3 joint publications

Paulo Thiago de Souza-Santos